All In Biotech

Drug Trial Radar · NCT04940624

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

144

Actual

Start

Oct 28, 2021

Primary completion

Apr 11, 2024

Study completion Apr 11, 2024

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of convulsive seizures in children and young adults with DS. Participants will receive their standard antiseizure therapy, plus either a tablet of soticlestat or placebo for 16 weeks. A placebo looks just like soticlestat but will not have any medicine in it. Participants may continue treatment in an extension study, based on the extension study's entry criteria. Those that want to stop treatment will have a gradual dose reduction during 1 week and then be followed up for 2 weeks.

Conditions

  • Dravet Syndrome (DS)

Interventions

  • SoticlestatDrug

    Soticlestat mini-tablets or tablets.

  • PlaceboDrug

    Soticlestat placebo-matching mini-tablets or tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Full Treatment PeriodTime frame: Baseline; Full Treatment Period: Weeks 1 to 16
  2. Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Maintenance PeriodTime frame: Baseline; Maintenance Period: Weeks 5 to 16

Locations

66 sites in 18 countries. Site status is shown where the registry gives one.

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • David Geffen School of Medicine at UCLA

    Los Angeles, California

  • University of California Benioff Children's Hospital

    San Francisco, California

  • Clinical Integrative Research Center of Atlanta

    Atlanta, Georgia

  • University of Iowa Hospitals & Clinics - (CRS)

    Iowa City, Iowa

  • NYU Comprehensive Epilepsy Center

    New York, New York

  • University of Toledo

    Toledo, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • Seattle Children's Hospital

    Seattle, Washington

  • Multicare Health System - Mary Bridge Pediatrics

    Tacoma, Washington

  • Queensland Childrens Hospital

    South Brisbane, Queensland, Australia

  • Universidade de Sao Paulo

    São Paulo, Brazil

  • Instituto de Neurologia de Curitiba (INC)

    Curitiba, Paraná, Brazil

  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Alberta Childrens Hospital

    Calgary, Alberta, Canada

  • Child and Family Research Institute

    Vancouver, British Columbia, Canada

  • Hospital For Sick Children

    Toronto, Ontario, Canada

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Beijing Children's Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

  • Children's Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Shenzhen Children's Hospital

    Shenzhen, Guangdong, China

  • Wuhan Childrens hospital

    Wuhan, Hubei, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Children's Hospital of Shanghai

    Shanghai, Shanghai Municipality, China

  • Children's Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Hopitaux de La Timone

    Marseille, France

  • Hopital Necker - Enfants Malades

    Paris, France

  • Hopital Robert Debre

    Paris, France

  • Schon Klinik Vogtareuth

    Vogtareuth, Bavaria, Germany

  • Klinikum der Johann-Wolfgang Goethe-Universitat

    Frankfurt am Main, Hesse, Germany

  • Krankenhaus Mara gGmbH - Epilepsiezentrum Bethel

    Bielefeld, North Rhine-Westphalia, Germany

  • Attikon University General Hospital

    Chaïdári, Attica, Greece

  • Orszagos Mentalis, Ideggyogyaszati es Idegsebeszeti Intezet

    Budapest, Hungary

  • IRCCS Ospedale Pediatrico Bambino Gesu - INCIPIT - PIN

    Rome, Lazio, Italy

  • Fondazione Policlinico Universitario A Gemelli

    Rome, Lazio, Italy

  • ASST di Pavia - Fondazione Istituto Neurologico Mondino IRCCS

    Pavia, Lombardy, Italy

  • Azienda Ospedaliero Universitaria A Meyer - INCIPIT - PIN

    Florence, Tuscany, Italy

  • Aichi Medical University Hospital

    Nagakute-Shi, Aiti, Japan

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.